HK2385A - Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them - Google Patents

Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them

Info

Publication number
HK2385A
HK2385A HK23/85A HK2385A HK2385A HK 2385 A HK2385 A HK 2385A HK 23/85 A HK23/85 A HK 23/85A HK 2385 A HK2385 A HK 2385A HK 2385 A HK2385 A HK 2385A
Authority
HK
Hong Kong
Prior art keywords
group
formula
compound
hydrogen
carbazolyl
Prior art date
Application number
HK23/85A
Other languages
German (de)
English (en)
Inventor
Fritz Dr. Wiedemann
Wolfgang Dr. Kampe
Max Dr. Thiel
Glabert Dr. Sponer
Egon Dr. Roesch
Karl Prof.Dr. Dietmann
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6036838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK2385(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of HK2385A publication Critical patent/HK2385A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (4)

1. Dérivés de carbazolyl-(4)-oxy-propanolami- ne de formule 1 dans laquelle:
R1 est un atome d'hydrogène, un groupe alca- noyle inférieur ou un groupe benzoyle ou naph- toyle,
R2 est un atome d'hydrogène, un groupe alkyle inférieur, ou un groupe benzyle, phényléthyle ou phénylpropyle,
R3 est de l'hydrogène ou un groupe alkyle inférieur,
R4 est de l'hydrogène ou un groupe alkyle inférieur,
X est un trait de valence, un groupe -CH2-, un atome d'oxygène ou un atome de soufre,
Ar est un reste phényle, naphtyle, indanyle, té- trahydronaphtyle ou pyridyle et
R5 et R6, pouvant être identiques ou différents sont chacun de l'hydrogène, du chlore, un groupe alkyle inférieur, un groupe amino carbonyle, une fonction hydroxyle, un groupe alcoxyle inférieur, un groupe benzyloxy, un groupe alkyl-mer- capto inférieur, un groupe alkylsulfinyle inférieur, un groupe alkylsulfonyle inférieur ou bien ils forment ensemble un groupe méthylènedioxy, et dans le cas où
X est un atome d'oxygène, R4 et R5 peuvent aussi désigner ensemble le groupe -CH20-,
ainsi que leurs sels physiologiquement tolérables.
2. Procédé pour la préparation des dérivés de carbazolyl-(4)-oxy-propanolamine selon la revendication 1 dans lesquels R1, R2, R3, R4, X, Ar, R5 et R6 ont la signification donnée ci-dessus, ainsi que leurs sels physiologiquement tolérables, caractérisé en ce que l'on fait réagir de façon en soi connue:
a) un composé deformule II dans laquelle Y est un groupe réactif et R1' a la signification donnée pour R1 ou bien Y et R1' forment ensemble un trait de valence, avec un composé de formule III dans laquelle R2, R3, R4, X, Ar, R5 et R6 ont la signification indiquée, ou,
b) un composé de formule IV dans laquelle R1 et R2 ont la signification indiquée, avec un composé de formule V dans laquelle Y, R3, R4, X, Ar, R5 et R6 ont la signification indiquée, ou,
c) un mélange d'un composé de formule IV et un composé de formule VI dans laquelle R3, R4, X, Ar, R5 et R6 ont la signification indiquée, en le soumettant à une réduction, ou,
d) un composé de formule IV avec un composé de formule VII dans laquelle Y, R4, X, Ar, R5 et R6 ont la signification indiquée, et on soumet l'amide obtenu à une réduction, et en ce qu'ensuite on transforme éventuellement les composés de formule 1 obtenus selon le procédé ci-dessus en d'autres composés de formule l, et les composés de formule I obtenus en leurs sels pharmacologiquement tolérables.
3. Utilisation des composés de formule I et de leurs sels pharmacologiquement tolérables pour la préparation de médicaments ayant une activité vasodilatrice et/ou une activité de blocage des β-récepteurs.
4. Médicaments comprenant une substance active de formule I ainsi que des substances de support pharmacologiquementtolérables.
HK23/85A 1978-04-13 1985-01-10 Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them HK2385A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782815926 DE2815926A1 (de) 1978-04-13 1978-04-13 Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
HK2385A true HK2385A (en) 1985-01-18

Family

ID=6036838

Family Applications (1)

Application Number Title Priority Date Filing Date
HK23/85A HK2385A (en) 1978-04-13 1985-01-10 Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them

Country Status (23)

Country Link
US (1) US4503067A (fr)
EP (1) EP0004920B1 (fr)
JP (2) JPS54157558A (fr)
AT (1) AT375639B (fr)
AU (1) AU522975B2 (fr)
BG (1) BG61419B2 (fr)
CA (1) CA1129416A (fr)
CS (2) CS227007B2 (fr)
DD (1) DD143607A5 (fr)
DE (2) DE2815926A1 (fr)
DK (1) DK154555C (fr)
ES (1) ES479396A1 (fr)
FI (1) FI70406C (fr)
HK (1) HK2385A (fr)
HU (1) HU179433B (fr)
IL (1) IL57020A (fr)
LT (1) LT2628B (fr)
LU (1) LU88320I2 (fr)
MX (1) MX9203380A (fr)
NL (1) NL930110I2 (fr)
SG (1) SG52284G (fr)
SU (1) SU810079A3 (fr)
ZA (1) ZA791732B (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131146A1 (de) * 1981-08-06 1983-02-24 Boehringer Mannheim Gmbh, 6800 Mannheim Neue heteroaryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
GB9113802D0 (en) * 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
US5405863A (en) * 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
ZA938897B (en) * 1992-12-01 1994-08-01 Smithkline Beecham Corp Antioxidant neuroprotective use of and method of treatment using hydroxycarbazole compounds
WO1994020096A1 (fr) * 1993-03-05 1994-09-15 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited Procede d'utilisation de carbazolyle-(4)-oxypropanolamine pour inhiber la proliferation de cellules de muscles lisses
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DE19628335A1 (de) * 1996-07-13 1998-01-15 Boehringer Mannheim Gmbh Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von peripheren Durchblutungsstörungen
AU4083097A (en) * 1996-08-23 1998-03-06 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership No. 1 Method for inhibiting the expression of fas
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
DE69711519T2 (de) * 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazolanaloge als selektive beta3-adrenergische Agonisten
WO1998015272A1 (fr) * 1996-10-09 1998-04-16 BOEHRINGER MANNHEIM PHARMACEUTICALS CORP. - SMITHKLINE BEECHAM CORPORATION, LIMITED PARTNERSHIP No.1 Procede d'inhibition de proteines kinases activees par contrainte
EP0893440A1 (fr) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Une modification thermodynamique stabilisée de 1-(4-carbazolyloxy)-3[2-(2-methoxyphenoxy)ethylamino]- 2-propanole, un procédé pour sa préparation et une composition pharmaceutique qui la contient
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
CN1285738A (zh) * 1997-11-12 2001-02-28 泊灵格曼海姆药品公司及史密斯克莱恩贝克曼公司 卡维地洛的新的口服剂型
HU227441B1 (en) * 1997-11-24 2011-06-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing carvedilol, enantiomers and salts thereof
HU9702209D0 (en) * 1997-11-24 1998-01-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical product
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
CA2326840C (fr) * 1998-04-09 2007-08-07 Roche Diagnostics Gmbh Medicaments galeniques a base de carvedilol
EP0968714A1 (fr) * 1998-07-02 2000-01-05 Roche Diagnostics GmbH Procédé de préparation de compositions pharmaceutiques à dissolution rapide contenant des agents actifs difficilement solubles
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
JP2003514019A (ja) 1999-11-15 2003-04-15 スミスクライン・ビーチャム・コーポレイション カルベジロールメタンスルホン酸塩
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
WO2001074356A1 (fr) * 2000-04-03 2001-10-11 F. Hoffmann-La Roche Ag Solutions concentrees de carvedilol
DK174645B1 (da) * 2000-05-18 2003-08-04 Gea Farmaceutisk Fabrik As Fremgangsmåde og mellemprodukter til fremstillingen af 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol og syreadditionssalte deraf
IL153688A0 (en) 2000-06-28 2003-07-06 Teva Pharma Carvedilol
EP1655285A1 (fr) * 2000-06-28 2006-05-10 Teva Pharmaceutical Industries Ltd. Procédé de préparation d'une forme crystalline de carvedilol (forme II)
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20050009897A1 (en) * 2001-04-02 2005-01-13 Karen Anderson Method of treatment
IN191028B (fr) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
JP2004534840A (ja) * 2001-07-13 2004-11-18 スミスクライン・ビーチャム・コーポレイション カルベジロール多型体
WO2003017046A2 (fr) * 2001-08-14 2003-02-27 Variant Holdings, Llc. Systeme de commercialisation de biens et de services utilisant des installations centrales et distantes informatisees
WO2003024430A1 (fr) * 2001-09-21 2003-03-27 Egalet A/S Systeme a liberation de polymere de morphine
EP1429739A1 (fr) 2001-09-21 2004-06-23 Egalet A/S Systeme de liberation a base de polymere
WO2003029214A1 (fr) * 2001-09-28 2003-04-10 F. Hoffmann-La Roche Ag Formes pseudopolymorphes de carvedilol
WO2003028718A1 (fr) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Nouvelles formulations de carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
PL371409A1 (en) * 2002-01-15 2005-06-13 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
JP2006500320A (ja) * 2002-04-30 2006-01-05 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール一クエン酸塩一水和物
JP2005530746A (ja) * 2002-05-03 2005-10-13 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロールファーマソルブ溶媒和物
AU2003231306A1 (en) * 2002-05-03 2003-11-17 Smithkline Beecham Pharmco Puerto Rico, Inc. Carvedilol formulations
MXPA04012923A (es) 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
AU2003251627A1 (en) 2002-06-27 2004-01-19 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
US20040152756A1 (en) * 2002-07-15 2004-08-05 Wei Chen Carvedilol polymorph
US20060013877A1 (en) * 2002-07-22 2006-01-19 Nanohybrid Co., Ltd. Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same
EP1545519B1 (fr) 2002-08-19 2011-03-23 Pfizer Inc. Therapie de combinaison pour maladies hyperproliferatives
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
AU2003275953A1 (en) * 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
SK285547B6 (sk) * 2002-11-08 2007-03-01 Zentiva, A. S. Spôsob prípravy Carvedilolu
WO2004094378A1 (fr) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Procede de fabrication de carvedilol, forme-ii
CN1812983A (zh) * 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg－co抑制剂的用途
US7482471B2 (en) * 2003-06-20 2009-01-27 Sun Pharmaceutical Industries Limited Process for preparation of 1-[9H-carbazol-4-yloxy]-3-[{2-(2-(-methoxy)phenoxy)-ethyl}-amino]-propan-2-ol
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
WO2005051322A2 (fr) 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Base libre de carvedilol, ses sels, formes anhydres ou solvates, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et procedes de traitement ou d'administration
WO2005115981A2 (fr) * 2004-04-22 2005-12-08 Usv Limited Nouveau procede de preparation de 1-(9h-carbazol-4-yloxy)-3-[[2-(-methoxyphenoxy)-ethyl] amino]-propan-2-ol
GB0411273D0 (en) * 2004-05-20 2004-06-23 Cipla Ltd Process and product
US20080255134A1 (en) * 2004-11-30 2008-10-16 Artesian Therapeutics, Inc. Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
CA2589699A1 (fr) * 2004-12-09 2006-06-15 Zach System S.P.A. Procede de preparation de carvedilol et de ses enantiomeres
US20070027202A1 (en) * 2005-06-07 2007-02-01 Ashok Kumar Process for the preparation of carvedilol and its salts
EP1781611A1 (fr) * 2005-06-09 2007-05-09 Teva Pharmaceutical Industries Ltd. Formes cristallines du carvedilol et leurs procedes de preparation
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
CA2625219A1 (fr) 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Nouveaux composes heterocycliques en tant qu'inhibiteurs de pstat3/il6
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2008020314A2 (fr) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Formulations de dosage stabilisantes à base de statine
US8703804B2 (en) 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
WO2008002683A2 (fr) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Carvédilol phosphate
WO2008010087A2 (fr) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited FORMES POLYMORPHES D'UN INHIBITEUR DE LA HMG-CoA-RÉDUCTASE ET LEURS UTILISATIONS
WO2008038301A1 (fr) * 2006-09-26 2008-04-03 Morepen Laboratories Limited Procédé pour la préparation de carvédilol
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008084494A1 (fr) * 2007-01-08 2008-07-17 Matrix Laboratories Limited Nouvelles formes polymorphes de dihydrogénophosphate de carvedilol et procédé de préparation de celles-ci
EP2104493A2 (fr) * 2007-01-16 2009-09-30 Egalet A/S Utilisation (i) d'un polyglycol et (ii) d'une substance médicamenteuse active dans la préparation d'une composition pharmaceutique destinée (i) à réduire le risque de libération massive induite par l'alcool et/ou (ii) à réduire le risque de toxicomanie médicamenteuse
CZ302357B6 (cs) * 2007-01-26 2011-03-30 Zentiva, A. S. Zpusob cištení Carvedilolu
US20080207726A1 (en) * 2007-02-26 2008-08-28 Santiago Ini Process for the purification of carvedilol or its salts thereof
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
WO2008142703A1 (fr) * 2007-05-17 2008-11-27 Wanbury Limited Nouveau procédé économique pour la production de phosphate de carvédilol
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US8278461B2 (en) * 2007-08-21 2012-10-02 Lupin Limited Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer
WO2009035535A2 (fr) * 2007-09-07 2009-03-19 Scinopharm Taiwan Ltd. Procédé de cristallisation de phosphate de carvédilol et produit obtenu par ce procédé
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US20090111998A1 (en) * 2007-10-25 2009-04-30 Srinivas Reddy Gade Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof
US8889728B2 (en) * 2008-03-04 2014-11-18 Lupin Limited Stable pharmaceutical compositions of carvedilol
WO2009115902A1 (fr) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. Procédé permettant de préparer du carvedilol par protection silyle d'amine substituée
WO2009115906A2 (fr) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. Procédé amélioré pour la préparation du carvédilol impliquant un dérivé d'halohydrine
US20110015247A1 (en) * 2008-04-04 2011-01-20 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
US7763645B2 (en) * 2008-05-23 2010-07-27 Wanbury Limited Carvedilol dihydrogen phosphate monohydrate
WO2010092589A2 (fr) * 2008-05-26 2010-08-19 Alkem Laboratories Ltd. Procédé de préparation du phosphate de carvédilol amorphe
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (fr) 2009-06-24 2010-12-29 Egalet A/S Formulations à libération contrôlée
TWI415604B (zh) 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof
BR112014014480A2 (pt) 2011-12-16 2017-06-13 3M Innovative Properties Co derivados de bisanidro-hexitol que contêm oxirano e usos dos mesmos
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US8492426B1 (en) * 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
US10357476B1 (en) 2018-10-30 2019-07-23 Anis Ahmad Method for treating coronary artery disease
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN111170997A (zh) * 2019-12-31 2020-05-19 广州医科大学 咔唑类化合物及其制备方法和应用
CN113372260A (zh) * 2021-07-05 2021-09-10 大连蒙迪科技有限公司 一种卡维地洛杂质的合成方法
CN115960032A (zh) * 2021-10-08 2023-04-14 复旦大学 具有β-arrestin偏向性激动活性的芳氧丙醇胺类β-肾上腺素受体配基及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1834015A (en) * 1929-06-29 1931-12-01 Gen Aniline Works Inc Manufacture of hydroxy carbazoles
DE1152107B (de) * 1956-06-27 1963-08-01 Chem Fab Promonta G M B H Verfahren zur Herstellung von basisch substituierten Carbazolderivaten und deren Salzen
US3932424A (en) * 1970-06-15 1976-01-13 Richardson-Merrell Inc. Bis-basic ethers of carbazole
BE789072A (fr) * 1971-09-23 1973-03-21 Astra Laekemedel Ab Composes abaissant le taux de lipides du serum et leur obtention
AT336176B (de) * 1971-12-10 1977-04-25 Sandoz Ag Verfahren zur herstellung eines pharmazeutischen praparates
US3975398A (en) * 1973-08-01 1976-08-17 Boehringer Mannheim G.M.B.H. 9-Substituted 3-aminocarbazole compounds
DE2339396C2 (de) * 1973-08-03 1984-06-28 Boehringer Mannheim Gmbh, 6800 Mannheim N-substituierte 1-Amino-3-phenoxypropan-2-ole, deren Salze, Verfahren zu deren Herstellung sowie Arzneimittel, die diese Verbindungen enthalten
DE2424523A1 (de) * 1974-05-21 1975-12-11 Boehringer Mannheim Gmbh Neue 1,2,3,4-tetrahydrocarbazol-derivate und verfahren zu deren herstellung
DE2454406A1 (de) * 1974-11-16 1976-05-20 Boehringer Mannheim Gmbh Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4076829A (en) * 1974-11-16 1978-02-28 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
US4152446A (en) * 1974-11-16 1979-05-01 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
GB1508208A (en) * 1975-12-05 1978-04-19 Ici Ltd Amide derivatives
US4115409A (en) * 1975-12-05 1978-09-19 Imperial Chemical Industries Limited Alkanolamine derivatives

Also Published As

Publication number Publication date
FI70406C (fi) 1986-09-19
AU522975B2 (en) 1982-07-08
FI70406B (fi) 1986-03-27
SG52284G (en) 1985-03-29
US4503067A (en) 1985-03-05
DK154555B (da) 1988-11-28
EP0004920B1 (fr) 1981-08-05
CS227007B2 (en) 1984-04-16
AT375639B (de) 1984-08-27
MX9203380A (es) 1992-09-01
JPS54157558A (en) 1979-12-12
LU88320I2 (de) 1994-05-04
LT2628B (lt) 1994-04-25
JPH0123462B2 (fr) 1989-05-02
NL930110I1 (nl) 1993-10-18
CA1129416A (fr) 1982-08-10
DE2815926A1 (de) 1979-10-18
FI791142A7 (fi) 1979-10-14
BG61419B2 (bg) 1997-07-31
AU4582079A (en) 1979-10-18
IL57020A0 (en) 1979-07-25
ES479396A1 (es) 1980-04-16
DK141979A (da) 1979-10-14
SU810079A3 (ru) 1981-02-28
NL930110I2 (nl) 1994-12-01
DK154555C (da) 1989-06-19
ZA791732B (en) 1980-05-28
JPS63258416A (ja) 1988-10-25
ATA276279A (de) 1984-01-15
CS420091A3 (en) 1992-04-15
DD143607A5 (de) 1980-09-03
DE2960553D1 (en) 1981-11-05
EP0004920A1 (fr) 1979-10-31
HU179433B (en) 1982-10-28
IL57020A (en) 1982-07-30

Similar Documents

Publication Publication Date Title
CA1129416A (fr) Derives de carbazolyl-(4)-oxypropanolamine
AU7077896A (en) Selective B3 adrenergic agonists
WO2005028426A1 (fr) Nouveau derive de 4-phenylamino-benzaldoxime et son utilisation en tant qu'inhibiteur de mek
EP0546583A1 (fr) Pipérazinyl- et pipéridinyl-cyclohexanols
CS228532B2 (en) Production method of phenylpiperazine derivative
EP0883613A1 (fr) Derives de sulfonamide en tant qu'antagonistes du recepteur de 5ht7
EP1608635B1 (fr) Derives de phenyl-sulfone et leur utilisation dans le traitement de troubles du systeme nerveux central (snc)
EP1660483B1 (fr) Derives de 8- (1-piperazinyl)- quinoleine et leur utilisation pour le traitement de troubles du systeme nerveux central
DK164907B (da) Piperazinderivater, deres fremstilling og farmaceutiske praeparater indeholdende dem
US3102115A (en) Sulfonylurea compounds
WO1999029673A1 (fr) AGONISTES ADRENERGIQUES SELECTIFS DE β¿3?
KR19990029067A (ko) 피페라진 유도체 및 ５­ｈｔ１ａ 길항제로서의 이의용도
US4281132A (en) Piperidino ureas and thioureas
US4067904A (en) Alkylsulfonylphenoxypropanolamine derivatives
CA1106846A (fr) Derives d'aminoalkoxyphenyle
AU609359B2 (en) New indolylpropanols, processes for their preparation and their use, and preparations containing the compounds
EP0061149B1 (fr) Dérivés du alkylènedioxybenzène et leurs sels d'addition acides et procédé pour leur préparation
IE48915B1 (en) Aminoalkoxyphenylpyrrolidones,process for their manufacture and their use
JPS6140674B2 (fr)
DK150197B (da) Analogifremgangsmaade til fremstilling af 2-substituerede 1-aminoalkoximino-cycloalkaner eller et syreadditionssalt eller quaternaert ammoniumderivat deraf
JPS6126992B2 (fr)
US4061640A (en) 2-(Benzamido piperidine) quinolyl derivatives
CA1040656A (fr) Preparation de derives de phenoxalkylamine
JPH01151561A (ja) フタラジン化合物、その製造方法、ならびにこの化合物を含有する心血管疾患および腫瘍の治療剤
JPS6055505B2 (ja) 新規オキシムエ−テル化合物及びその製造方法

Legal Events

Date Code Title Description
PE Patent expired